Diagnostic (ferumoxytol-enhanced MRI) for Childhood Brain Tumor

Phase-Based Progress Estimates
Childhood Brain TumorDiagnostic (ferumoxytol-enhanced MRI) - DiagnosticTest
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial looks at whether an MRI scan enhanced with ferumoxytol can show whether there is inflammation in the brain of children with cancer.

Eligible Conditions
  • Childhood Brain Tumor

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Days 2-4

Day 1
Iron concentration measurements
Days 2-4
Macrophages on histopathology

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Diagnostic (ferumoxytol-enhanced MRI)
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Diagnostic (ferumoxytol-enhanced MRI) · No Placebo Group · Phase < 1

Diagnostic (ferumoxytol-enhanced MRI)Experimental Group · 4 Interventions: Surgery, Diagnostic (ferumoxytol-enhanced MRI), Ferumoxytol, Tissue Analysis · Intervention Types: Procedure, DiagnosticTest, Drug, Other
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: days 2-4

Who is running the clinical trial?

Michael IvLead Sponsor
1 Previous Clinical Trials
10 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,098 Previous Clinical Trials
41,145,797 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: